Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, hypertension, blood pressure reduction, glycemic control, HbA1c, combination antihypertensive therapy, renin-angiotensin system inhibitors, insulin, adverse events, drug safety, ambulatory blood pressure monitoring, cardiovascular risk reduction, renal protection, diabetic nephropathy, diabetic retinopathy, diabetic maculopathy, diabetic neuropathy, diabetic cardiomyopathy, diabetic osteoporosis
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W2187514862
